Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It contains specific transaction details for a share purchase:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.4900 per share.
- Transaction Volume: 363.463 shares.
- Transaction Date: July 14, 2016.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Mr. D S Redfern, Chief Strategy Officer. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's Deferred Investment Award Programme. No material changes to the company's financial position are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of a specific executive share transaction.
Key Facts for Investor Verification
- Verify the identity of the PDMR: Mr. D S Redfern, Chief Strategy Officer.
- Confirm the transaction nature: Dividend re-investment under the Deferred Investment Award Programme.
- Note the transaction price of £16.4900 and volume of 363.463 shares.
- Understand that this filing does not contain quarterly or annual financial performance data.